Effect of an angiotensin II receptor antagonist, TCV-116, on rat carotid artery neointimal formation after balloon injury

Blood Press Suppl. 1994:5:43-8.

Abstract

Arterial injury by a balloon catheter produces marked smooth muscle cell proliferation and the participation of angiotensin II in this response has been suggested. In this study, we examined the effect of a novel angiotensin II type I receptor antagonist, TCV-116, on neointimal formation after rat carotid artery balloon injury. Oral administration of TCV-116 at doses of 1, 5 or 10 mg/kg/day significantly reduced the cross-sectional intimal area by 30%, 46% and 54%, respectively, and reduced the ratio of the intimal to medial cross-sectional areas by 23%, 41% and 50%. An angiotensin-converting enzyme inhibitor, lisinopril, had an effect similar to that of TCV-116. The effect of both drugs was significantly correlated with the reduction of both blood pressure and cardiac hypertrophy. We conclude that TCV-116 can prevent neointimal formation after balloon injury as well as reducing blood pressure and preventing cardiac hypertrophy.

Publication types

  • Comparative Study

MeSH terms

  • Angiotensin Receptor Antagonists*
  • Animals
  • Antihypertensive Agents / therapeutic use*
  • Arteriosclerosis / etiology
  • Arteriosclerosis / pathology
  • Arteriosclerosis / prevention & control
  • Benzimidazoles / therapeutic use*
  • Biphenyl Compounds / therapeutic use*
  • Blood Pressure / drug effects
  • Carotid Artery Diseases / etiology*
  • Carotid Artery Diseases / pathology
  • Carotid Artery Diseases / prevention & control*
  • Carotid Artery, Common / drug effects
  • Carotid Artery, Common / pathology
  • Catheterization / adverse effects*
  • Hypertension / drug therapy
  • Lisinopril / therapeutic use
  • Male
  • Prodrugs / therapeutic use*
  • Rats
  • Rats, Inbred SHR
  • Rats, Sprague-Dawley
  • Tetrazoles*
  • Tunica Intima / drug effects*
  • Tunica Intima / pathology*

Substances

  • Angiotensin Receptor Antagonists
  • Antihypertensive Agents
  • Benzimidazoles
  • Biphenyl Compounds
  • Prodrugs
  • Tetrazoles
  • Lisinopril
  • candesartan cilexetil